JPMorgan analyst Eric Joseph reiterated an Overweight rating and $62.00 price target on Akero Therapeutics (NASDAQ: AKRO).The analyst comments "In ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Akero Therapeutics (AKRO) declines after efruxifermin NASH trial readout disappoints; Is it time to buy?October 10, 2023 8:26 AM Canaccord on Akero Therapeutics (AKRO): 'We would be strong buyers on this weakness'October 10, 2023 8:21 AM Form 8-K Akero Therapeutics, Inc. For: Oct 10October 10, 2023 8:05 AM Cantor Fitzgerald on Akero Therapeutics (AKRO), 'we expect the stock to trade down'October 10, 2023 7:55 AM 89bio Inc. (ETNB) Trades Lower in Sympathy with Akero Therapeutics (AKRO)October 10, 2023 7:17 AM Akero Therapeutics (AKRO) Falls 48% Following 6-Week Analysis of 96-Week Phase 2b SYMMETRY Study for NASHOctober 10, 2023 7:07 AM Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY StudyOctober 10, 2023 7:00 AM Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of LOctober 10, 2023 7:00 AM After-hours movers: Akero Therapeutics gains ahead of data, PagerDuty falls on conv. offeringOctober 9, 2023 5:39 PM Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASHOctober 9, 2023 4:05 PM